Article Details

Gilead Forges NASH Deal With insitro as It Continues to Take Aim at the Liver Disease

Retrieved on: 2019-04-15 21:41:15

Tags for this article:

Click the tags to see associated articles and topics

Gilead Forges NASH Deal With insitro as It Continues to Take Aim at the Liver Disease. View article details on hiswai:

Excerpt

<div>... Gilead, insitro also secured $100 million in a Series A funding round led by Arch Venture Partners, Foresite Capital, GV and <b>Third Rock Ventures</b>.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up